Xencor Inc Earnings

The next earnings date for Xencor Inc is November 10, 2025.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Xencor Inc Earnings

Report DateEstimated Earnings Per Share
11/10/2025$-0.70

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Xencor Inc Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
08/05/2025---$0100.00%
07/30/2025---$0100.00%
05/07/2025Before Market$-0.66-13.60%
02/25/2025Before Market$-0.6221.14%
11/05/2024Before Market$-0.7127.55%
08/05/2024After Market$-1.07-21.59%
05/09/2024After Market$-1.11-40.51%
02/27/2024After Market$-0.31-244.44%
11/07/2023After Market$-0.4045.21%
08/03/2023After Market$-0.3753.75%
05/08/2023After Market$-1.02-54.55%
02/23/2023After Market$-0.2074.68%
11/07/2022After Market$-0.5519.12%
08/03/2022After Market$-0.57-29.55%
05/05/2022After Market$0.39163.93%
02/23/2022After Market$1.211,310.00%
11/08/2021After Market$-0.69-6.15%
08/04/2021After Market$0.87255.36%
05/05/2021After Market$-0.0494.03%
02/23/2021After Market$-0.2436.84%
11/05/2020After Market$-0.224.35%
08/04/2020After Market$-0.61-22.00%
05/07/2020After Market$-0.1463.16%
02/24/2020After Market$-0.47-14.63%
11/05/2019After Market$-0.1867.27%
08/06/2019After Market$-0.2839.13%
05/09/2019After Market$1.381,433.33%
02/25/2019After Market$-0.3234.69%
11/05/2018After Market$0.05109.62%
08/06/2018After Market$-0.464.17%
05/07/2018After Market$-0.62-37.78%
02/27/2018After Market$-0.2528.57%
11/07/2017After Market$-0.330.00%
08/07/2017After Market$-0.1540.00%
05/09/2017After Market$-0.31-29.17%
02/28/2017After Market$-0.2134.38%
11/02/2016After Market$-0.200.00%
08/02/2016After Market$1.13727.78%
05/02/2016After Market$-0.1640.74%
03/07/2016After Market$0.19163.33%
11/03/2015After Market$-0.25-47.06%
08/04/2015After Market$-0.22-22.22%
05/04/2015After Market$-0.19-11.76%
02/19/2015After Market$-0.0477.78%
11/10/2014After Market$-0.20-5.26%
07/31/2014---$-0.1615.79%
05/14/2014---$-0.1225.00%
03/19/2014---$-0.24-71.43%

More About Xencor Inc

Website
https://www.xencor.com
Country
USA
Full Time Employees
250

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn's disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer's disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

“Xencor Inc Earnings” Can Refer to the Xencor Inc Earnings Date

Some people say “Xencor Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Xencor Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Xencor Inc Stock on the Earnings Date

If you own Xencor Inc stock (XNCR) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Xencor Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Xencor Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Xencor Inc Earnings

You can contact us any time if you would like to ask questions about Xencor Inc earnings or anything else related to the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.